Trial Profile
Dosing to rash? - The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions; Biomarker
- 10 Feb 2016 New trial record
- 25 Jan 2016 Results published in the European Journal of Cancer